{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:25:29Z","timestamp":1790807129333,"version":"4.1.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaceclinicalcasereports.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["AACE Clinical Case Reports"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.aace.2023.10.002","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T07:37:59Z","timestamp":1698392279000},"page":"209-212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Osteoporosis Improved by Romosozumab Therapy in a Patient With Type I Osteogenesis Imperfecta"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7306-3681","authenticated-orcid":false,"given":"Antara","family":"Dattagupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Petak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.aace.2023.10.002_bib1","first-page":"367","article-title":"Current and emerging treatments for the management of osteogenesis imperfecta","volume":"6","author":"Monti","year":"2010","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"10.1016\/j.aace.2023.10.002_bib2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s11914-014-0225-0","article-title":"Osteogenesis imperfecta: diagnosis and treatment","volume":"12","author":"Biggin","year":"2014","journal-title":"Curr Osteoporos Rep"},{"issue":"1","key":"10.1016\/j.aace.2023.10.002_bib3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11657-011-0054-z","article-title":"Bone mass, bone markers and prevalence of fractures in adults with osteogenesis imperfecta","volume":"6","author":"Wekre","year":"2011","journal-title":"Arch Osteoporos"},{"key":"10.1016\/j.aace.2023.10.002_bib4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1080\/03009742.1998.11720768","article-title":"Osteoporosis during pregnancy and its management","volume":"107S","author":"Smith","year":"1998","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.aace.2023.10.002_bib5","first-page":"1017","article-title":"Osteoporosis: pathophysiology and therapeutic options","volume":"19","author":"F\u00f6ger-Samwald","year":"2020","journal-title":"EXCLI J"},{"issue":"23","key":"10.1016\/j.aace.2023.10.002_bib6","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/ajhp\/zxaa285","article-title":"Romosozumab: a first-in-class sclerostin inhibitor for osteoporosis","volume":"77","author":"Prather","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.aace.2023.10.002_bib7","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2147\/DDDT.S127568","article-title":"Profile of romosozumab and its potential in the management of osteoporosis","volume":"11","author":"Lim","year":"2017","journal-title":"Drug Des Devel Ther"},{"issue":"16","key":"10.1016\/j.aace.2023.10.002_bib8","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"9418","key":"10.1016\/j.aace.2023.10.002_bib9","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","article-title":"Osteogenesis imperfecta","volume":"363","author":"Rauch","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.aace.2023.10.002_bib10","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.1542\/peds.2006-2023H","article-title":"Bisphosphonates: mode of action and pharmacology","volume":"119","author":"Russell","year":"2007","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.aace.2023.10.002_bib11","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3390\/medicina57050464","article-title":"Current overview of osteogenesis imperfecta","volume":"57","author":"Deguchi","year":"2021","journal-title":"Medicina (Kaunas)"},{"issue":"7","key":"10.1016\/j.aace.2023.10.002_bib12","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1210\/clinem\/dgad035","article-title":"Approach to the patient: pharmacological therapies for fracture risk reduction in adults with osteogenesis imperfecta","volume":"108","author":"Liu","year":"2023","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.aace.2023.10.002_bib13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/14712598.2017.1280455","article-title":"Romosozumab for the treatment of osteoporosis","volume":"17","author":"Bandeira","year":"2017","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"10.1016\/j.aace.2023.10.002_bib14","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/mrcr\/rxab018","article-title":"Efficacy of romosozumab for osteoporosis in a patient with osteogenesis imperfecta: a case report","volume":"6","author":"Uehara","year":"2022","journal-title":"Mod Rheumatol Case Rep"}],"container-title":["AACE Clinical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2376060523001438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2376060523001438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:32:35Z","timestamp":1762497155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2376060523001438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2376060523001438"],"URL":"https:\/\/doi.org\/10.1016\/j.aace.2023.10.002","relation":{},"ISSN":["2376-0605"],"issn-type":[{"value":"2376-0605","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osteoporosis Improved by Romosozumab Therapy in a Patient With Type I Osteogenesis Imperfecta","name":"articletitle","label":"Article Title"},{"value":"AACE Clinical Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aace.2023.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 AACE. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}